Omega, Jabre Capital Among Hedge Fund Casualties in Dismal 2018 (Bloomberg)
(Bloomberg) — It has been yet another year to forget in the world of hedge funds. Hardly a month went by without news of the high-fee money managers — young and old, running large and small shops, big and little-known names — shutting down. Many struggled to navigate markets marked by violent stock swings and slumping oil prices, others decided to restructure their firms to make riskier or longer-term bets, while some said they simply had enough of trading. Now as the year comes to a close, the $3.2 trillion industry is headed for its worst annual performance since 2011. Despite the slew of high-profile managers from T. Boone Pickens to Leon Cooperman throwing in the towel, hedge funds are closing at the slowest pace since 2007, when 563 shut down, according to Hedge Fund Research.
Billionaire Israel Englander Throws in the Towel on Advanced Micro Devices (AMD) Stock, Pours More Money Into Intel (INTC) (SmarterAnalyst.com)
Israel Englander is the chairman and CEO of Millennium Management LLC, a hedge fund that manages more than $35 billion. Englander – whose father’s side of the family was killed in the Holocaust – began his career as an intern at Oppenheimer & Co. and worked in multiple Wall Street firms after college before launching Millennium in 1989. Englander is worth $6 billion and is also active in philanthropy, including his Englander Foundation, which he launched with his wife in 2006. Millennium is among the world’s largest hedge funds, and Englander is one the most successful fund managers today.
Up 70% In 2018, Is Herbalife a Buy? (The Motley Fool)
Shares of Herbalife (NYSE:HLF) have raced 70% higher this year, smashing the broader stock market’s 8% decline as of this writing. Hedge fund manager Bill Ackman said he exited his bet against Herbalife early in 2018; paired with rebounding sales and share repurchases, investors who believed in the nutritional supplements company should be quite pleased. After a banner year, though, a repeat performance might be a tall order to ask. 2018 by the numbers: Ackman bet against Herbalife years ago because, as he said at the time, the company was a “pyramid scheme” whose stock would “go to zero.”
Insider Buying: Red Lion Hotels Co. (RLH) Major Shareholder Buys 109,832 Shares of Stock (MareaInformativa.com)
Red Lion Hotels Co. (NYSE:RLH) major shareholder Coliseum Capital Management acquired 109,832 shares of the business’s stock in a transaction on Wednesday, December 26th. The shares were purchased at an average cost of $7.39 per share, for a total transaction of $811,658.48. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission.
Amkor Technology, Inc. (AMKR) Insider Buys $949,500.00 in Stock (ModernReaders.com)
Amkor Technology, Inc. (NASDAQ:AMKR) insider Stephen Douglas Kelley acquired 150,000 shares of the company’s stock in a transaction on Tuesday, December 11th. The stock was purchased at an average cost of $6.33 per share, for a total transaction of $949,500.00. Following the completion of the transaction, the insider now owns 168,750 shares in the company, valued at approximately $1,068,187.50. The purchase was disclosed in a document filed with the SEC.
Insider Buying: Lazydays Holdings Inc (NASDAQ:LAZY) Director Acquires 198,627 Shares of Stock (PressOracle.com)
Lazydays Holdings Inc (NASDAQ:LAZY) Director Coliseum Capital Management, L acquired 198,627 shares of the firm’s stock in a transaction that occurred on Friday, December 14th. The shares were bought at an average cost of $5.34 per share, for a total transaction of $1,060,668.18. The purchase was disclosed in a filing with the SEC.
Insider Selling: Consumer Portfolio Services, Inc. (NASDAQ:CPSS) Director Sells 23,631 Shares of Stock (BaseballDailyDigest.com)
Consumer Portfolio Services, Inc. (NASDAQ:CPSS) Director Greg Washer sold 23,631 shares of the firm’s stock in a transaction on Friday, December 14th. The shares were sold at an average price of $3.41, for a total value of $80,581.71. Following the completion of the sale, the director now directly owns 323,430 shares of the company’s stock, valued at approximately $1,102,896.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Insider Buying: Odonate Therapeutics Inc (ODT) CEO Acquires 60,000 Shares of Stock (MareaInformativa.com)
Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang purchased 60,000 shares of Odonate Therapeutics stock in a transaction dated Wednesday, December 26th. The stock was bought at an average price of $12.60 per share, for a total transaction of $756,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission.
Insider Selling: Acorda Therapeutics Inc (NASDAQ:ACOR) Major Shareholder Sells 61,857 Shares of Stock (ModernReaders.com)
Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 61,857 shares of the firm’s stock in a transaction on Friday, December 14th. The shares were sold at an average price of $16.21, for a total value of $1,002,701.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.